FDA Grants Fast Track to NKGen’s Natural Killer Therapy for Alzheimer’s

NKGen Biotech, Inc, a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer cell therapeutics, announced that the US Food and Drug Administration (FDA) has granted fast track designation for the investigation of troculeucel, ex vivo expanded autologous natural killer cell therapy, for the treatment of moderate Alzheimer’s disease.

The US FDA fast track designation is intended to accelerate the development and review process for therapies addressing serious health conditions and unmet medical needs and offers hope for faster access to promising new treatments.

“We are pleased with the US FDA’s decision to grant Fast Track designation for troculeucel. This decision underscores the significant unmet need for effective treatments for patients with moderate AD. We specifically targeted the moderate stage population as they represent about 30% of all Alzheimer’s cases and most, if not all, of the current focus has been on early/mild patients,” said Paul Y. Song, MD, Chairman and CEO of NKGen. “This designation comes after promising safety and efficacy results from our phase 1 trial, which shows early signs of clinical benefit in patients treated with troculeucel. Receiving fast track designation will significantly accelerate the drug development process, bringing us one step closer to delivering this promising therapy to Alzheimer’s disease  patients in need, and ensuring faster access to a potentially life-changing treatment.”

NKGen is currently enrolling patients in its phase 2a trial for moderate Alzheimer’s disease and expects to share updated clinical data by the end of 2025.

The US FDA Fast Track designation is intended to facilitate the development and expedite the review of drug candidates to treat serious medical conditions and fulfill unmet medical needs. To qualify for this designation, both clinical and non-clinical data must demonstrate the drug candidate’s potential to address the identified medical need. A drug granted Fast Track status may benefit from enhanced communication with the US FDA throughout the development process, and, if applicable criteria are met, may also qualify for accelerated approval and priority review as well as for a rolling review of the regulatory dossier.

Troculeucel is a novel cell-based, patient specific ex vivo expanded autologous natural killer cell, immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name for SNK01 assigned by the World Health Organization (WHO). The WHO International Nonproprietary Name approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on our journey toward bringing this therapy to market.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!